ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

Summary

This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.

Timeline

Start

2024-06-07

Primary completion

2024-06-07

Completion

2024-06-07

Outcome

Outcome not reported

Stopped (Business): “Lack of Funding - no safety issue with Drug; Company Permanently Closed”

Drugs

Indications